Chordate Medical has developed Kinetic Oscillation Stimulation (KOS) which is an intranasal treatment that provides a preventive effect for chronic migraine and chronic nasal congestion (rhinitis).
In August 2022, the company completed a large patient study, PM007, with KOS in 132 patients with chronic migraine. People with chronic migraine suffer from headaches at least 15 days per month, of which more than 8 days are migraine. The primary efficacy endpoint in the PM007 study was to reduce the number of monthly headache days of moderate to severe intensity, an objective that was achieved with significance.
Positive results from PM007
In the study, 67 of the patients received active KOS treatment, while 65 patients received a validated sham/placebo treatment. The patients who received active treatment showed a significant reduction in the number of monthly headache days of moderate to severe intensity, compared with the patients who received sham treatment. The difference from baseline was shown using the least squares method of analysis of covariance, also known as ANCOVA analysis.
American Headache Society
Chordate conducted the study at five neurological clinics in Germany and four in Finland. The company has previously presented subgroup results from the German part of the study and now the American Headache Society has published the final results in the form of an abstract on their website.
The American Headache Society (AHS) is an organization dedicated to improving the lives of people with headaches and other related conditions. The society is comprised of researchers and physicians dedicated to the study and treatment of headaches. Each year, the AHS organizes a scientific conference, and this year’s edition will be held in Austin, Texas, June 15-18. Researchers from Chordate Medical’s PM007 study will be on hand to present the KOS treatment and study results.
Study results benefit marketing work
The study showed that KOS has a sustained treatment effect and that the treatment is well tolerated without any serious side effects. This makes the treatment different from other preventive treatments on the market through its favorable side effect profile.
Based on the results, the company concludes that KOS is an effective and safe treatment option for the preventive treatment of chronic migraine. Furthermore, the treatment is drug-free, which makes it a valuable addition to the current treatment regimen.
Chordate Medical is currently introducing the migraine treatment in Italy, Finland, Germany, the UK and Israel. The fact that ASH has now published the results could benefit the establishment of the treatment, according to the company's CEO Anders Weilandt:
»The fact that AHS has chosen to have the researchers in the study present in lecture format confirms the importance of the study results, which show that KOS has a significant and clear effect for the preventive treatment of chronic migraine. We see the regular publication of the abstract as very positive, as it will contribute to the faster spread of knowledge about the treatment method both in the United States and the rest of the world.«